342 related articles for article (PubMed ID: 28881380)
1. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
Hoskins PJ; Gotlieb WH
CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380
[TBL] [Abstract][Full Text] [Related]
2. Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
Hoskins PJ
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):472-483. PubMed ID: 29735311
[TBL] [Abstract][Full Text] [Related]
3. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
4. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
George A; Kaye S; Banerjee S
Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297
[TBL] [Abstract][Full Text] [Related]
5. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
6. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903
[TBL] [Abstract][Full Text] [Related]
7. BRACAnalysis CDx as a companion diagnostic tool for Lynparza.
Gunderson CC; Moore KN
Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709
[TBL] [Abstract][Full Text] [Related]
8. Genetic testing in ovarian cancer - clinical impact and current practices.
Knabben L; Imboden S; Mueller MD
Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
[TBL] [Abstract][Full Text] [Related]
9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
[TBL] [Abstract][Full Text] [Related]
11. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH
Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
14. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
15. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Trainer AH; Meiser B; Watts K; Mitchell G; Tucker K; Friedlander M
Int J Gynecol Cancer; 2010 Jul; 20(5):704-16. PubMed ID: 20973257
[TBL] [Abstract][Full Text] [Related]
16. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
[TBL] [Abstract][Full Text] [Related]
17. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105
[TBL] [Abstract][Full Text] [Related]
19. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ
Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231
[TBL] [Abstract][Full Text] [Related]
20. The integration of BRCA testing into oncology clinics.
Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S
Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
